|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 471/18 | (2006.01) |
| A61K 31/4162 | (2006.01) | ||
| A61P 7/02 | (2006.01) |
| (11) | Number of the document | 3293186 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17189935.4 |
| Date of filing the European patent application | 2015-07-29 | |
| (97) | Date of publication of the European application | 2018-03-14 |
| (45) | Date of publication and mention of the grant of the patent | 2020-09-23 |
| (46) | Date of publication of the claims translation | 2020-12-28 |
| (30) | Number | Date | Country code |
| 201462058316 P | 2014-10-01 | US |
| (72) |
DILGER, Andrew K., US
CORTE, James R., US
DE LUCCA, Indawati, US
FANG, Tianan, US
YANG, Wu, US
WANG, Yufeng, US
PABBISETTY, Kumar Balashanmuga, US
EWING, William R., US
ZHU, Yeheng, US
WEXLER, Ruth R., US
PINTO, Donald J.P., US
ORWAT, Michael J., US
SMITH II, Leon M., US
|
| (73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543-4000,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Pirimidinonai kaip faktoriaus XIa inhibitoriai |
| PYRIMIDINONES AS FACTOR XIA INHIBITORS |
| Payment date | Validity (years) | Amount | |
| 2025-06-19 | 11 | 289.00 EUR |
| 2026-07-29 |